Therapeutic principles of primaquine against relapse of Plasmodium vivax malaria

Conference item

Abstract:: Plasmodium vivax causes tens of millions of clinical attacks annually all across the malarious globe. Unlike the other major cause of human malaria, Plasmodium falciparum, P. vivax places dormant stages called hypnozoites into the human liver that later awaken and provoke multiple clinical attacks in the weeks, months, and few years following the infectious anopheline mosquito bite. The only available treatment to prevent those recurrent attacks is primaquine (hypnozoitocide), and it must be administered with the drugs applied to end the acute attack (blood schizontocides). This paper reviews the therapeutic principles of applying primaquine to achieve radical cure of acute vivax malaria.

Files:: Baird_2018_IOP_Conf._Ser.__Earth_Environ._Sci._125_012098.pdf

(Preview, Version of record, pdf, 489.0KB, Terms of use)

Publisher:: IOP Publishing
Host title:: IOP Conference Series: Earth and Environmental Science
Journal:: IOP Conference Series: Earth and Environmental Science More from this journal
Volume:: 125
Article number:: 012098
Series:: IOP Conference Series
Publication date:: 2018-03-26
Acceptance date:: 2018-02-01
DOI:: 10.1088/1755-1315/125/1/012098
EISSN:: 1755-1315
ISSN:: 1755-1307

Copyright holder:: JK Baird
Notes:: © JK Baird 2018. Published under licence by IOP Publishing Ltd. Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI. This paper was presented at the 1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI), November 2017, Medan, Indonesia.

If you are the owner of this record, you can report an update to it here: Report update to this record